Compare GCTK & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCTK | GRI |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.9M |
| IPO Year | 2011 | 2020 |
| Metric | GCTK | GRI |
|---|---|---|
| Price | $1.58 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $644.00 |
| AVG Volume (30 Days) | 205.9K | ★ 338.7K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17910.53 | N/A |
| EPS | ★ 30.09 | N/A |
| Revenue | ★ $589,462.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.09 | $0.18 |
| 52 Week High | $15.90 | $11.12 |
| Indicator | GCTK | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 25.95 | 53.72 |
| Support Level | $1.52 | $1.21 |
| Resistance Level | $4.24 | $2.87 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | 0.07 | -0.09 |
| Stochastic Oscillator | 24.48 | 52.73 |
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.